Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

被引:0
|
作者
Papayannidis, Cristina [1 ]
Sartor, Chiara [2 ]
Dominietto, Alida [3 ]
Zappone, Elisabetta [4 ]
Marconi, Giovanni [2 ]
Abbenante, Maria Chiara [5 ]
Parisi, Sarah [2 ]
Robustelli, Valentina [2 ]
Terragna, Carolina [1 ]
Nanni, Jacopo [2 ]
Soverini, Simona [2 ]
Cristiano, Gianluca [2 ]
Arpinati, Mario [1 ]
Paolini, Stefania [1 ]
Martinelli, Giovanni [6 ]
Curti, Antonio [1 ]
Cavo, Michele [2 ]
Bonifazi, Francesca [1 ]
机构
[1] Azienda Osped Univ St Orsola Malpighi, Ist Ematol, Bologna, Italy
[2] Univ Bologna Osped St Orsola Malpighi, Ist Ematol Seragnoli, Bologna, Italy
[3] IRCCS Osped Policlin San Martino, Genoa, Italy
[4] AOUS Siena, Policlin Scotte, UOC Ematol, Siena, Italy
[5] UOC Ematol, Casa Cura Sollievo Sofferenza, San Giovanni Rotondo, Italy
[6] IRST Ist Sci Romagnolo Cura & Studio Tumori, Meldola, Italy
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词
acute lymphoblastic leukemia; ALL; inotuzumab ozogamicin; donor lymphocyte infusion;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ALL-073
引用
收藏
页码:S161 / S161
页数:1
相关论文
共 50 条
  • [21] The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloblative hematopoietic stem cell transplant (HSCT).
    Maris, MB
    Sandmaier, BM
    Niederwieser, D
    Maloney, DG
    McSweeney, PA
    Chauncey, T
    Shizuru, J
    Sahebi, F
    Blume, K
    Forman, S
    Storb, R
    BLOOD, 2000, 96 (11) : 477A - 477A
  • [22] SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)-AN OPTION TO CONSIDER
    Duerst, R. E.
    Jacobson, D.
    Chaudhury, S.
    Schneiderman, J.
    Tse, W. T.
    Kletzel, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 81 - 81
  • [23] Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation
    Tachibana, Takayoshi
    Tanaka, Masatsugu
    Takasaki, Hirotaka
    Numata, Ayumi
    Fujisawa, Shin
    Maruta, Atsuo
    Harada, Hiroshi
    Mori, Hiraku
    Ishigatsubo, Yoshiaki
    Kanamori, Heiwa
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (06) : 580 - 582
  • [24] Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation
    Takayoshi Tachibana
    Masatsugu Tanaka
    Hirotaka Takasaki
    Ayumi Numata
    Shin Fujisawa
    Atsuo Maruta
    Hiroshi Harada
    Hiraku Mori
    Yoshiaki Ishigatsubo
    Heiwa Kanamori
    International Journal of Hematology, 2011, 94 : 580 - 582
  • [25] Factors associated with allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO) versus (v) conventional chemotherapy (C).
    Kebriaei, Partow
    DeAngelo, Daniel J.
    Stelljes, Matthias
    Gokbuget, Nicola
    Kantarjian, Hagop M.
    Advani, Anjali S.
    Merchant, Akil
    Wang, Tao
    Loberiza, Fausto Rodriguez
    Sleight, Barbara
    Vandendries, Erik
    Marks, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
    Wang, Tao
    Gao, Lei
    Hu, Xiaoxia
    Liu, Bin
    Chen, Jie
    Zhang, Weiping
    Wang, Jianmin
    Yu, Xuejun
    Feng, Dongge
    Chang, Alfred E.
    Max, Wicha
    Tang, Gusheng
    Li, Qiao
    Yang, Jianmin
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (03) : 81 - 88
  • [27] GVHD FOLLOWING TISAGENLECLEUCEL FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
    Moskop, Amy
    Phelan, Rachel
    Atallah, Ehab
    Anderson, Lynnette
    Rao, Sidhar
    Margolis, David
    Talano, Julie
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S229 - S230
  • [28] Outcome of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in relapsed myelodysplastic syndrome
    Marumo, Atsushi
    Nagata, Yasunobu
    Fujioka, Machiko
    Kurosawa, Shuhei
    Najima, Yuho
    Sakaida, Emiko
    Doki, Noriko
    Fukushima, Kentaro
    Ota, Shuichi
    Shono, Katsuhiro
    Ito, Ayumu
    Uchida, Naoyuki
    Nishida, Tetsuya
    Sawa, Masashi
    Tsunemine, Hiroko
    Matsuoka, Ken-ichi
    Fukuda, Takahiro
    Makoto, Onizuka
    Kanda, Yoshinobu
    Itonaga, Hidehiro
    CYTOTHERAPY, 2025, 27 (02) : 222 - 228
  • [29] Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation
    Uslu, Atilla
    Seval, Guldane Cengiz
    Bozdag, Sinem Civriz
    Gurman, Gunhan
    Demirer, Taner
    Arslan, Onder
    Ozcan, Muhit
    Toprak, Selami Kocak
    Topcuoglu, Pervin
    Ilhan, Osman
    BONE MARROW TRANSPLANTATION, 2018, 53 : 161 - 162
  • [30] Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion
    Tamai, H.
    Shioi, Y.
    Yamaguchi, H.
    Okabe, M.
    Wakita, S.
    Mizuki, T.
    Nakayama, K.
    Inokuchi, K.
    Tajika, K.
    Dan, K.
    LEUKEMIA, 2008, 22 (06) : 1273 - 1274